Clinical Trial

Melatonin for Treatment of Delirium in Critically Ill Adult Patients

Study acronym: DELIRE-ICU
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to determine the feasibility of conducting a randomized controlled trial (RCT) with melatonin for treatment of delirium in critically ill adult patients. From a feasibility perspective, the investigators believe that the proposed design will achieve the minimum enrollment rate necessary to conduct a future RCT on a larger scale.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2023-01-26; most recent amendment 2026-03-19.
Status change: Not Yet Recruiting → Recruiting 2023-02-23
Trial Details
NCT Number NCT05713877
Lead Sponsor Ciusss de L'Est de l'Île de Montréal
Collaborators: Maisonneuve-Rosemont Hospital
Conditions Delirium
Enrollment 30 participants
Start Date 2023-02-01
Primary Completion 2026-12-30 (estimated)
Study Completion 2026-12-30 (estimated)
Updated on ClinicalTrials.gov 2026-03-23